TEM vs RLAY
TEM and RLAY side by side — valuation & fundamentals (public data).
Key statistics
| Metric | TEMTempus AI, Inc. | RLAYRelay Therapeutics, Inc. |
|---|---|---|
| Market cap | $12.34M | $4.16B |
| P/B | 0.03 | — |
| P/S | 0.0x | 270.9x |
| Revenue | $1.43B(TTM) | — |
| Revenue growth (YoY) | 83.4% | 53.4% |
| Net income | -$254.40M(TTM) | — |
| Earnings growth (YoY) | 65.3% | 18.1% |
| EPS, diluted | $-1.44(TTM) | — |
| EBIT margin | -19.9% | -1971.6% |
| ROE | -55.1% | -31.1% |
| 1y total return | -19.2% | +368.1% |
Figures from SEC filings · for reference only · not investment advice
Growth of $10,000: TEM vs RLAY
| Metric | TEM | RLAY |
|---|---|---|
| End value | $17.1K | $26.0K |
| Total return | +71.1% | +159.5% |
| CAGR | +26.9% | +52.7% |
| Volatility | 97.6% | 78.6% |
| Sharpe | 0.68 | 0.86 |
| Sortino | 1.09 | 1.48 |
| Max drawdown | -59.8% | -79.0% |
Based on 564 common trading days, 2024-06-14 → 2026-09-15 · risk-free 4.11% (current short-Treasury, held constant)
A head-to-head total-return backtest over real split- and dividend-adjusted prices: how a one-time $10,000 investment in each stock, held to today, would have grown over their common window — including reinvested dividends. A disclosed historical statistic — NOT a prediction, a guarantee, or investment advice. Past performance does not predict future results.
Related comparisons
Delayed data · Public sources · For reference only · Not investment advice (this page declares no winner)